Loading...
Sorafenib, the only approved first-line therapy for hepatocellular cancer (HCC), has limited activity (mainly disease stabilization) and a modest impact on progression-free and overall survival. It also has considerable toxicities, leading to dose reduction or treatment discontinuation.
To determine the effect of reducing the starting dose of sorafenib in this setting, investigators have now conducted a large retrospective analysis of 4903 HCC patients from 128 Veterans Health Administration hospitals who were treated with sorafenib between 2006 and 2015. Of these, 63% received the standard starting dose of sorafenib (400 mg twice daily) and 37% received a reduced starting dose (<400 mg twice daily). Compared with standard-dose recipients, r…